

2

3 **Formulation Development and Evaluation of Fast Dissolving**

4 **Oral Films of Alprazolam**

5

6 **ABSTRACT**

7 Fast dissolving oral films provide convenient, safe and simple way of drug
8 administration. Moreover they offer improved patient compliance due to
9 straightforward and non-invasive nature. The aim of current research was to develop
10 fast dissolving oral films of alprazolam for treatment of anxiety disorders. Films were
11 developed by solvent casting method using HPMC (Hydroxypropyl Methyl Cellulose)
12 as film former and PEG (Polyethylene Glycol) as plasticizer. All formulation (F1-
13 F12) were assessed for various parameters including thickness, tackiness, percent
14 elongation, folding endurance, tensile strength, contact angle, transparency, content
15 uniformity, disintegration and dissolution times. The thickness of optimized
16 formulation was found to be 65µm and the Tensile strength, Percent elongation,
17 Folding Endurance, Transparency, Contact angle, Assay/ content uniformity,
18 Disintegration Time and Dissolution for optimized formulation were found to be
19 5.38%, 45%, 290 times, 100.1%, 180°, 98.65%, 20seconds and 106.6% respectively.
20 Drug release studies displayed 106.60% release of total drug content after time
21 duration of 1.813 minutes. The results of the study concluded that newly developed
22 fast dissolving film of alprazolam have potential to provide fast delivery of the drug
23 and thereby enhanced patient compliance.

24

25 **Key Words:**

26 Fast Dissolving Oral Films, Alprazolam, film formers.

27

28

29 **1 INTRODUCTION**

30 Therapeutic agents can be administered through different routes including oral,
31 parenteral etc. (Dixit *et al.*, 2009) however, dysphagia and fear of choking are
32 commonly found in all age groups (Saini *et al.*, 2011). Fast dissolution of oral dosage
33 forms is a wide field and comprises of three types of formulation and dosage
34 development. **Lyophilized technology, Fast Dissolving Oral Dispersible Tablets,**
35 **Fast Dissolving Oral Thin Films (FDOF)** (Bhyan *et al.*, 2011), (Saini *et al.*, 2011).
36 Fast dissolving oral tablets are the innovation in oral route of drug administration as
37 they overcome limitations of others. This innovation was introduced in 19th century
38 that leads to Fast Dissolving Oral Films (FDOF) (Arya *et al.*, 2010).


39 They quickly disintegrate and dissolve hence this technique is important for the drugs
40 that have poor aqueous phase solubility (NIMBAL *et al.*, 2013). These are innovations
41 in oral route with no fear of choking or injection, also no need of fluid intake. (Patel *et*
42 *al.*, 2010), (Damle *et al.*, 2013). This dosage form also augments safety and
43 effectiveness of therapeutic agents by evaluation of a dosage form that is easy in
44 administration and compatible to patient use (Shirsand *et al.*, 2008), (Arya *et al.*,
45 2010). Various over the counter and potent medicines are under era of development.
46 Because of advantages of fast dissolving oral films will be the most demanding
47 dosage in the near future (Pandya, 2013). Thickness of these oral films vary from 50-
48 200nm (Mandeep *et al.*, 2013). Depending upon method of manufacturing and release
49 mechanism fast dissolving oral films are divided into three different types. **Flash**
50 **Release, Mucoadhesive melt-away wafers, Mucoadhesive sustained release**
51 **wafers** (Bala *et al.*, 2013). Fast dissolving films of Granisetron Hydrochloride were
52 developed that showed better results than its other oral dosage forms (Rathore *et al.*,
53 2019)

54 **1.1. Oral Route of Administration**

55 Oral route includes buccal, sublingual and sublabial administration. It is the most
56 accepting route (Gandhi *et al.*, 1994).

57 Bioavailability of therapeutic drug substance experiences great variation via this
58 route. As the pH of enteral tract varies greatly so oral route of administration is
59 effective for drugs with varying pK_a values and moderate to high oral bioavailability
60 and acid stable products (Rowland, 1972). Also this route is applicable only for the

61 drugs with no data of G.I irritations. Other factors are: Emptying of Gastric tract,
62 Intestinal motility, Nature of food, Intestinal metabolism and transport, Hepatic
63 metabolism (Gwee *et al.*, 1999).




64

65 **Figure 1:** Anatomy and physiology of oral cavity

66 1.2 Drug Profile & Pharmacokinetics

67 Alprazolam is a potent therapeutic ingredient. It is a short acting benzodiazepine with
68 benzene group at 1 and 4 positions of compound and also a minor tranquillizer. It is
69 prescribed for the treatment of specialized anxiety disorders e.g mania & pania and
70 also in generalized anxiety disorders e.g agoraphobia. When we are concerned with
71 mechanism of action of Alprazolam, it immediately binds to GABA receptors and
72 causes potentiation. Pharmacokinetics of Alprazolam when administered orally shows
73 absorption i.e eighty to ninety percent with peak plasma concentration of about 12-22
74 $\mu\text{g/L}$. Volume of distribution V_d for Alprazolam is 1-1.3L/kg. $T_{1/2}$ is 9-16hrs and
75 about 0.8-1.5ml of drug can be cleared from the body per kilogram of body weight.
76 Orally Alprazolam is 80-100% bioavailable and show its therapeutic effects (Damle *et*
77 *al.*, 2013).



78

79 **Figure 2:** Structure of Alprazolam

80 1.3 Candidate Drugs for Fast Dissolving Oral Films

81 Many drugs which are more potent and have low therapeutic dose like antitussives,
82 expectorants, antiasthmatics, antiepileptic can be formulated in film form for the
83 patients suffering from Gastrointestinal disorders, Nausea, Pain or Central Nervous
84 System (CNS) disorders.

85 **Table 1:** Commercially available brands of FDOF (Bhyan *et al.*, 2011)

Sr. #	Product	Manufacturer	API
1.	Cough Suppressant	Monosol Rx	Dextromethorphan HBr
2.	Cough/cold Suppressant	Monosol Rx	Diethylhydramine Citrate
3.	Breath Strips	Monosol Rx	Cool Mint
4.	Rapid Dissolving Films	Labtec Pharma	Ondansatrom
5.	Rotavirus Vaccine	John Hopkin Undergraduate biomedical engineering students	Rotavirus Vaccine for infants
6.	Fast dissolving films	Hughes Medical Cooperation	Methycobalamine
7.	Fast dissolving films	Hughes Medical Cooperation	Diphenhydramine HCl
8.	Fast dissolving films	Hughes Medical Cooperation	Folic Acid
9.	Fast dissolving films	Dow Chemical Company	Bezocain
10.	Fast dissolving films	Dow Chemical Company	Caffeine

86

87 1.4 Alprazolam Dosage Forms

88 Lots of research work is available on oral tablet, parenteral and aerosol dosage from
89 of alprazolam (Mahaguna *et al.*, 2003), (Evans, 1993). Sublingual tablets of
90 alprazolam were formulated and efficacy was compared with that of conventional
91 tablets (Márquez *et al.*, 2011). Commercially available formulations of alprazolam
92 and diazepam injections comprise one or more solvents to solubilize. These
93 components tend to precipitate while injected in aqueous media (Yalkowsky *et al.*,
94 1983). Aerosol systems of Alprazolam comprises of about 5% w/w of active
95 pharmaceutical ingredient delivered to a mammal through inhalation route
96 (Rabinowitz *et al.*, 2004).

97

98 **1.4.1 Advantages**

99 As in case of panic disorders and other anxiety abnormalities dose of alprazolam is
100 three to four times per day. After introduction of sustained, controlled and extended
101 released tablets patient non-compliance of taking unit dose repeatedly has been
102 overcome.

103 **1.4.2 Limitations**

104 Dysphagia is commonly found in all age groups. Because of this effect more than half
105 of patient population does not feel convenient in taking oral solid dosage forms like
106 tablets. While taking oral tablets patients especially pediatric and geriatrics experience
107 a fear of choking. Due to these reasons there is patient non-compliance for the
108 dosage form. Furthermore fluid intake is required for the administration of tablets of
109 alprazolam while in case of fast dissolving oral films there would be no need of water
110 as film disintegrate through saliva and dissolve API contents. Tablets take 15minutes
111 to disintegrate as per official standards while on the other hand disintegration time for
112 oral films is only within 5-30 seconds. Hence there is rapid dissolution of alprazolam.

113 In case of parental formulations as they are contain one or more co-solvents in their
114 formulations; there is a chance of precipitation while they are administered in aqueous
115 media. Patient non-compliance with respect to pain of injection. For inhalations of
116 alprazolam there is need to educate patient for use of inhaler. As alprazolam is
117 controlled drug there could be a chance of mishandling of aerosol sprays of
118 alprazolam that result in difficulties (O'Sullivan *et al.*, 1994).

119 **1.5 Problem Statement**

120 The conventional dosage forms of alprazolam such as tablets are administered 3-4
121 times by patients suffering from anxiety disorders. There are problems associated with
122 parenteral dosage forms like precipitation in aqueous media and patient education is
123 mandatory for inhalation therapy. Oral films are considered as patient friendly
124 alternatives of conventional dosage forms and thus gained tremendous attention in the
125 recent years. Oral films are regarded as a customized or personalized dosage form for
126 patients like pediatrics, geriatrics, bed-ridden and patient with different diseases.
127 Going through literature, we found limited information for evaluation of alprazolam
128 in the form of oral films. Therefore, to address the issues posed by the conventional

129 dosage forms of alprazolam, we made an attempt to develop oral films of alprazolam
130 with different polymers and evaluated their physicochemical characteristics.

131 **2 Formulation Development**

132 **2.1.1 Formulation Considerations**

133 Typical Fast Dissolving Oral Films contain following major components Active
134 Pharmaceutical Ingredient (API), Film Forming Polymers, Plasticizers, Sweetening
135 Agents, Saliva stimulating agent, Flavoring agent and Coloring agent (if required).

136 These ingredients could vary in concentration as per compatibility of API with
137 excipient or excipient with other excipient. Usually concentration limits of these
138 ingredients used for film formation are: Active Pharmaceutical Ingredient...1-30%
139 w/w, Film Forming Polymers...40-45% w/w, Plasticizers...0-20% w/w, sweetening
140 agents...quantity sufficient, Saliva Stimulating Agents...3-6% w/w, Flavoring
141 Agents... quantity sufficient, Coloring Agent... quantity sufficient (Siddiqui *et al.*,
142 2011). Drugs with small molecular weight and potent drugs are very good candidates
143 for development of formulation of fast dissolving oral films (Bhyan *et al.*, 2011).

144 **2.1.2 Film Forming Polymers**

145 Wide variety of polymers is available and used in the development of films.
146 Synthetic, semisynthetic, hydrophilic polymers are used. Normally a film contains
147 about 45% of film forming polymer by weight (Nagar *et al.*, 2011).

148 **2.1.3 Overview of Polymers**

149 The polymers used in the formulation of fast dissolving strips should be devoid of
150 leachable impurities, non-toxic and non-irritant. Some of them are discussed below
151 together with their film forming abilities and physicochemical properties.

152 **2.1.4 Plullan**

153 *Aureobasidium pullulans* is fungus-like yeast which produces the polymer plullan.
154 The composition of plullan includes glucan which in turn made of three glucose
155 molecules and maltotriose units (Cheng *et al.*, 2010).

156 Plullan is available as white amorphous, tasteless powder with no descriptive odor. It
157 chars at 280°C and starts to decompose at 250°C. Regarding solubility it forms a clear

158 solution in water and alkaline solutions and insoluble in organic solvents (Graham,
159 1993).

160 **2.1.5 Gelatin**

161 Gelatin is composed of proteins fractions. It is soluble in water above 40 °C. Its
162 physical properties are closed to the amino acid composition as well as molecular
163 weight distribution (Killekar et al., 2012). Gelatin film produce a smooth mouth feel,
164 excellent carriers for flavors and was found to dissolve rapidly (Yougyata *et al.*,
165 2013).

166 **2.1.6 Chitosan**

167 It is also an important polymer for better characterization of film. It contains
168 glycopyranose rings in its structure. It forms a viscous polymer material that is porous
169 in appearance but films developed by it are uniform n thickness, compact and
170 cohesive (Yogyata *et al.*, 2013).

171 **2.1.7 Hydroxypropyl Methyl Cellulose (HPMC)**

172 Hydroxypropyl Methyl Cellulose is actually a cellulose derivative that is composed of
173 methylated, hydropropyl cellulose. It has been divided into different grades depending
174 upon solubility and temperature sensitivity. Lower grades of HPMC like Methocel
175 E3, E5, and E15 have low viscosity and are particularly used for film formation.
176 HPMC can also used for aqueous coating but it has poor water solubility (Priyank *et*
177 *al.*, 2011).

178 **2.2 Plasticizer**

179 Plasticizers are the ingredients that are used to improve and maintain the brittleness of
180 oral films that concerned with the folding endurance of final unit dosage form.
181 Concentration limit of plasticizers for this purpose is 0-20% w/w of dry polymer used
182 alone or in combination (Bhyan *et al.*, 2011). These includes Propylene Glycol (PG),
183 Glycerol, Polyethylene Glycol (PEG) e.g. PEG-400, PEG-600, PEG-2000, PEG-4000,
184 PEG-6000, Caster Oil etc. (Haff *et al.*, 1985).

185 **2.3 Sweeteners**

186 Sweeteners are the agents that are used to mask the unpleasant taste of oral dosage
187 forms and also in fast dissolving oral films. Usually they are used as per requirement

188 however within concentration limit of about 3-6% w/w. Classification of sweeteners
189 includes natural and artificial sweeteners. Sorbitol, mannitol, Saccharin sodium,
190 Aspartame, Cyclamate Sodium, Sucralose are some famous examples of sweetening
191 agents.

192 **2.4 Saliva Stimulating Agent**

193 Saliva stimulating agents are used to enhance the production of saliva. Increased
194 production of saliva is required for mucoadhesion of oral films that further helps in
195 better penetration of oral film through oral cavity which latter results in better release
196 and absorption of therapeutic ingredient. Citric acid is the most common and easily
197 available example of saliva stimulating agents. Further such examples are lactic acid,
198 malic acid etc. They are used within concentration limit of 2-6% w/w of unit
199 formulation of film. Flavouring agents and colorants are also used.

200 **3 MATERIALS AND METHODS**

201 **3.1 Materials**

202 Alprazolam was received as gift for research purpose from Arsons Pharmaceutical
203 Industries Pvt. Ltd. HPMC E5 was purchased from Shandong Landu, China. HPMC
204 E15 was obtained from Shandong Landu, China. PEG-400 was purchased from Hebei
205 Shuangniu, China. PEG-6000 was purchased from India. Aspartame was purchased
206 from Singapore. Citric Acid Monohydrate was purchased from Shandong Landu,
207 China. Fresh distilled water was obtained from distillation plant of Arsons
208 Pharmaceutical Industries Pvt. Ltd.

209 **3.2 Methods**

210 **3.2.1 Compatibility Studies**

211 Drug excipient compatibility studies were conducted using Fourier Transform
212 Infrared Technique (FTIR) and no interaction was observed between the active and
213 the excipients (BEYATRICKS, 2019).

214 Fourier Transform Infrared spectrophotometer (FT-IR) spectral measurements were
215 performed using Agilent Technologies, Model No. Cary 630 Fourier transforms
216 infrared spectrophotometer. The pure drug and pure drug along with polymer mixture
217 were mixed together for analysis of interaction between these mixtures. The scans
218 were collected for Alprazolam and Alprazolam with other excipients and also

219 excipients with other excipients. The scans were collected in the range of 4000-400
220 cm^{-1}

221 **3.2.2 Formulation Development**

222 **3.2.2.1 Preparation of Fast Dissolving Oral Films of Alprazolam**

223 Casting of film forming solution was practiced for the development of fast dissolving
224 oral films. In this method HPMC E5 and E15 were used as water soluble polymers.
225 This film forming agent was dissolved in 10ml of water on continuous stirring by
226 magnetic stirrer for about 10minutes until a clear solution had been formed on hot
227 plate. Then PEG-400 was added as plasticizer in the same mixture of polymer. Hold
228 this solution for cooling and defoaming. After this alprazolam was dissolved in 10ml
229 water and mixed for 10 minutes by using magnetic stirrer. Then excipient phase and
230 active phase were mixed together. At the end sweetening agent: aspartame, saliva
231 stimulating agent: citric acid and menthol crystals were added in the solution. Then
232 solution was casted on petridish and dried at 40-45°C for 24hours. After complete
233 drying the film was carefully removed from the petri dish and cutted into 2 x 3 cm^2 and
234 wrapped in aluminium foil and stored in desiccators below 30°C for further
235 evaluation.

236 **3.3 Calculation of Dose**

237 Dose of Alprazolam was calculated by the formula was calculated as 0.0039gm of
238 Alprazolam per petri dish of 11cm of diameter (Akca *et al.*, 2018).

239 The Diameter of Petri dish is of 11 cm

$$\begin{aligned} 240 \text{ Area of circle (Petridish)} &= \pi r^2 \\ 241 &= 3.14 \times (5.5)^2 \\ 242 &= 94.985 \text{ cm}^2 \end{aligned}$$

243 Size of strip 3cm x2 cm

$$244 \text{ Area of film of 3cm x2 cm} = 6 \text{ cm}^2$$

245 The Alprazolam concentration to be present in one strip = 0.25mg/strip

246 The drug Alprazolam calculated for the Area 94.985 cm^2 of Petri dish = 3.96mg

247 **3.4 Characterization of Film**

248 **3.4.1 Assay Determination Of Alprazolam By HPLC**

249 Special Apparatus, Reagents and Solution include Suitable high-pressure liquid
250 chromatograph (Schimatzo) equipped with a UV detector at 231 nm and connected
251 with computing system. Chromatographic column, 25cm x 4.6mm (i.d.) 5 μ Hypersil
252 BDS-C18 (Schimatzo). Glass fibber Filter (type GF/A available from Whatman,
253 Ultrasonic bath, Distilled water. **Mobile phase** was formed by mixing filtered and
254 degassed solutions of methanol, acetonitrile and water in ratio of 10%, 60% and 30%
255 respectively.

256 Filter through 0.2-micron membrane & degas the solution in an Ultra sonic bath for 5
257 minutes.

258 **3.4.1.1 Chromatographic Conditions:**

259 High-pressure liquid chromatograph was equipped with a UV detector at 231 nm and
260 connected with computing system. Chromatographic column 25cm x 4.6mm (i.d.), 5 μ
261 Hypersil BDSC18. Glass fibber Filter (type GF/A available from Whatman. 20 μ L
262 injection was inserted at a flow rate of 1.5ml/min at ambient temperature. **Standard**
263 **Solution:** 50 mg of Alprazolam was weighed and transferred into a 50 ml volumetric
264 flask, then dissolved in 20ml of Mobile Phase and diluted to volume with the same.
265 Solution was filtered through a Whatman 2 filters, discarding the first 10ml of filtered
266 solution. Then 1 ml of the filtered solution was transferred into a 50 ml volumetric
267 flask and diluted to the mark with Mobile Phase. Final solution was sonicated for 3
268 minutes filtered to use. **Sample solution:** Take film sample of alprazolam equivalent
269 to 1 mg Alprazolam into a 50ml volumetric flask, dissolve in 20 ml of Mobile Phase
270 and dilute to volume with the same. Filtered through a Whatman filters, discarding the
271 first 10 ml of filtered solution and collect the filtrate. Sonicate for 3 minutes filter and
272 use. **Chromatographic Procedure:** Base line of chromatographic system was
273 stabilized by running blank solution. Then standard solution run through the mobile
274 phase and chromatograms were collected. After standardization of system procedure
275 same dilutions of sample solution were injected one by one and chromatograms were
276 recorded. **Limits:** The contents of Alprazolam should be 90-110% of the stated
277 amount (U.S.P pharmacopoeia).

278

279

Table-2 : Composition of Formulations

Ingredients	Formulation Code											
	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
Alprazolam (gm)	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039	0.0039
HPMC E5 (gm)	0.350	0.400	0.370	0.350	0.200	0.400	0.450	0.300	0.500	0.500	0.500	0.200
HPMC E15 (gm)	-	-	-	-	-	-	-	-	-	-	-	0.300
PEG 400 (gm)	-	-	0.300	0.300	0.300	0.250	0.350	0.300	0.250	0.300	0.300	0.300
Aspartame (gm)	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020	0.0020
Citric Acid Monohydrate (gm)	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003
Menthol Crystals (gm)	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010	0.0010
Distilled Water (ml)	20	20	20	20	20	20	20	20	20	20	20	20

280 **4 RESULTS**

281 **4.1 Drug Excipient Compatibility**

282 Fourier Transform Infrared spectrophotometer (FT-IR) spectral measurements were
283 performed using fourier transform infrared spectrophotometer (Agilent Technologies,
284 Canada). The therapeutic ingredient and the mixture of drug and excipient were
285 analyzed for finding out any interaction between drug and polymer. The scans were
286 recorded in the range of 4000-400 cm^{-1} .

287 The structure of alprazolam showed the aroamtic functional groups (C-C) of arene,
288 azarene, benzene and hetroarene. CHN containing amine group, (N-N) imine group,
289 iminyl group, halogen containing arylchloride and arylhalide and a leaving group. The
290 peak area near 1400 to 1600 cm^{-1} represents aromatic functional groups. Peak area
291 near 1330-1400 cm^{-1} represents C-H bonding in structure of alprazolam, peak area
292 near 1420 cm^{-1} represents CHN bonding instructure. IR band of (N-N) imine group
293 appeared around 3150-3300 cm^{-1} . From these results it was concluded that all the
294 functional groups of alprazolam showed peaks and there was no any incompatibility
295 between alprazolam and any excipients used.

296

297

298

299


300

301

302

303

304



326 **Figure 3:** FTIR spectra of alprazolam standard v/s sample (A), mixture of alprazolam
 327 and HPMC E5 (B), mixture of alprazolam and HPMC E15 (C), mixture of alprazolam and PEG 400 (D),
 328 mixture of alprazolam and menthol (E), mixture of drug and all the used excipients (F).
 329

330


331 **4.2 Development of Fast Dissolving Oral Films**

332 Fast Dissolving Oral Films of Alprazolam were developed by using water soluble film
333 forming agents alone or in combination with other polymers and PEG400 was used as
334 plasticizer by solvent casting method. Quantity of polymer and plasticizer was varied
335 and results for different formulations were observed and reported. Furthermore
336 quantities of sweetener and saliva stimulant were kept constant for better observation
337 of results for polymer and plasticizer behavior.

338

339

340




341

342 **Figure 4:** Fast dissolving oral film manufactured by casting method

343 **4.3 Linearity**

344 Testing method validation of alprazolam was carried out by evaluating and analyzing
345 assay at different concentrations of alprazolam. The stock solution was
346 gravimetrically diluted in mobile phase to concentrations of 0.005mg/ml, 0.01mg/ml,
347 0.02mg/ml, 0.03mg/ml, 0.04mg/ml and 0.05mg/ml respectively and area of curve was
348 tabulated in table 3.

349 A Linear straight line shows that the analytical method is validated.



350


351 **Figure 5:** The calibration graph showing linear relationship between the
 352 concentration and peak area of anylate in solution. Six sample solutions of different
 353 concentrations were prepared i.e 0.005mg/ml, 0.01mg/ml, 0.02mg/ml, 0.03mg/ml,
 354 0.04mg/ml and 0.05mg/ml and readings taken to observe peak areas for relationship
 355 between concentration and peak area. It was observed that as the concentration of
 356 anylate increases the peak area also increases.

357 **Table 3:** Quantitative assay of Alprazolam, an active pharmaceutical ingredient of
 358 film

Sr. #	Concentration mg/ml	Injection #	Retention Time(min)	Peak Area	Avg. peak area
1.	0.005	1A	1.808	1087.54	1095.81
		1B	1.807	1099.02	
		1C	1.810	1100.87	
2.	0.01	2A	1.807	2011.10	2010.55
		2B	1.810	2010.54	
		2C	1.809	2010.01	
3.	0.02	3A	1.808	3799.10	3793.06
		3B	1.812	3778.98	
		3C	1.811	3801.12	
4.	0.03	4A	1.809	5601.10	5544.79
		4B	1.814	5542.26	
		4C	1.809	5491.01	
5.	0.04	5A	1.809	7322.23	7308.90
		5B	1.809	7394.16	
		5C	1.812	7210.32	
6.	0.05	6A	1.812	9122.10	9136.99
		6B	1.812	9119.99	
		6C	1.812	9168.87	

359 4.4 Thickness

360 Six samples were analyzed from each formulation for the purpose of measurement of
361 thickness of fast dissolving oral film. The thickness of formulated film was observed
362 from five different places (four corners and one center of film) by calibrated
363 micrometer screw gauge and average was taken, results were in the range of 35 μ m to
364 66 μ m as shown in figure 6. Furthermore the average thickness of formulation F₁ was
365 35 μ m, F₂ was 40 μ m, F₃ was 54 μ m, F₄ was 55 μ m, F₆ was 63 μ m, F₇ was 65 μ m, F₈ was
366 64 μ m, F₉ was 66 μ m, F₁₀ was 65 μ m, F₁₁ was 64 μ m, F₁₂ was 70 μ m.



367

368 **Figure 6:** Graph showing average thickness of different formulations from F₁ - F₁₂. X-
369 axis represents the formulations and y-axis represents the thickness in μ m of film.

370 4.5 Dryness/ Tack Test


371 This is the physical test for films. Film must be dried enough that it could not be
372 stuck to the surface of its packing material. There is no criterion for this
373 characterization but it could be observed physically that either film showed any
374 tackiness or not. For this characterization six films from each formulation were
375 pressed in aluminium foil individually and their stickiness or adherence to foil was
376 observed and adherence was checked. Films were observed physically that they are
377 set to touch, dust free, tack free (with dry surface), dry to touch, dry hard, dry to
378 handle, dry to re-coat and print free.

379 4.6 Tensile Strength

380 The stressing force applied outward to the film at its edges until it breaks is the tensile
381 strength of film. To calculate the value of tensile strength the force required to rupture

382 or break the film was divided with cross sectional dimensions of film i.e thickness and
383 the width of film.

384 Six fast dissolving oral films from each formulation were analyzed for tensile strength
385 and load applied at breakage point was observed and tensile strength was calculated
386 as shown in figure 7. Furthermore it was observed that average tensile strength for
387 formulations F₁ to F₁₂ was 1.43, 2.50, 1.85, 1.82, 1.32, 3.17, 5.38, 3.12, 3.03, 3.85,
388 2.34, 2.85 N/cm² respectively.



389

390 **Figure 7:** Graph showing average tensile strength of different formulations from F₁ -
391 F₁₂. X-axis represents the formulations and y-axis represents the tensile strength of
392 film.


393 4.7 Percent Elongation

394 The percent increase in length of film when a stretching force is applied to it is called
395 the percent elongation. It is the change in shape or deformation of film divided by its
396 cross sectional area. Percent elongation was performed for six samples from each
397 formulation by using tensile strength tester. Generally elongation of film increases as
398 the plasticizer content increases. It could also be calculated by subtracting the final
399 length of film from its initial length i.e before applying stretching force and dividing
400 with initial length of strip.

401 Generally elongation of strip increases as the plasticizer content increases.

402 This test was performed by tensile strength tester. Initially length of film was
403 measured and then film was placed between the jaws of instrument and the point
404 where film near to break was noted. At this point the increase in length of fast
405 dissolving oral film was measured with the help of vernier calliper and percent

406 elongation was calculated by given formula. It was observed that the average percent
 407 elongation for formulations F₁ to F₁₂ was 10, 20, 10, 13.3, 10, 20.7, 45, 20, 16.7, 26.7,
 408 16.7, 40 respectively.




409

410 **Figure 8:** Graph showing % elongation of different formulations from F₁ - F₁₂X-axis
 411 represents the formulations and y-axis represents the percent elongation of film.

412 **4.8 Folding Endurance**

413 Folding endurance is the ability of film that how many times it could be folded
 414 without any crack or breakage. It was performed by repeated folding of the strip at the
 415 same place till the strip breaks. For each formulation six samples were analyzed for
 416 folding endurance and it was observed that folding endurance for formulations F₁ to
 417 F₁₂ was 120, 232, 230, 180, 208, 210, 290, 242, 200, 283, 150 and 123 respectively.



418

419 **Figure 9:** Graph showing folding endurance of different formulations from F₁ - F₁₂X-
 420 axis represents the formulations and y-axis represents the folding endurance of the
 421 film.

422

4.9 Transparency

Transparency shows that how much the film is free from any foreign particle or any haziness of casted solution as the transparency of film matters for its physical appearance. Six film samples were examined by putting their suitable size as per cell of U.V spectrophotometer. The transmittance of films was determined at 600 nm. The transparency of the films was calculated as follows:

$$\text{Transparency} = (\log T_{600})/b = -\epsilon c$$

In this equation T represents the transmittance of film, b is the thickness of film and c is the concentration at which formulation was developed. The average transmittance observed for formulations F₁ to F₁₂ was 87.7%, 99.8%, 99.9%, 99.9%, 87.7%, 100.00%, 100.1%, 87.2%, 100.1%, 99.9%, 100.6% and 82.2% respectively.





Figure 10: Graph showing transmittance of different formulations from F₁ - F₁₂. X-axis represents the formulations and y-axis represents the transmittance at 600nm. U.V Spectrophotometer was used for checking transmittance of film. Parameters of UV. Spectrophotometer were setted on transmittance. Wavelength setted at 600nm and reading was taken after calibration or autozeroing the instrument.

4.10 Contact Angel


Contact angle was measured to judge the wetting property of film that to how much extent water will adhere and swells the film. A drop of distilled water was dropped and readings were taken within ten seconds. The average contact angle observed for formulations F₁ to F₁₂ was 120°, 140°, 134°, 154°, 141°, 138°, 180°, 176°, 170°, 170°, 177° and 168° respectively.



455 **Figure 11:** Graph showing contact angle of different formulations from F₁ - F₁₂. X-axis represents the formulations and y-axis represents the angle that the water formed at the surface of film.

4.11 Assay/ Content Uniformity

459 Assay/Content Uniformity on films of all the formulations (F₁-F₁₂) was measured by
 460 following method described earlier and results were recorded by using HPLC
 461 (Schimatzo) as shown in figure 12. The content uniformity observed for formulations
 462 F₁ to F₁₂ was 98.64%, 100.99%, 99.44%, 101.44%, 101.62%, 99.18%, 98.65%,
 463 102.02%, 101.06%, 101.40%, 101.40%, 102.02%, 99.29% respectively.




464

465 **Figure 12:** Graph showing % assay of different formulations from F₁ - F₁₂. X-axis represents the formulations and y-axis represents the assay results in percentage.
 466 Assay was performed using high-pressure liquid chromatograph that was
 467 equipped with a UV detector at 231 nm and connected with computing system.
 468 Chromatographic column 25cm x 4.6mm (i.d.), 5 μ Hypersil BDSC18. Glass fiber
 469 Filter (type GF/A available from Whatman. 20 μ L injection was inserted at a flow
 470 rate of 1.5ml/min at ambient temperature.
 471

4.12 Disintegration Time

473 Disintegration time is the time taken by the film to disintegrate in water. According to
 474 CDER guidelines the time taken by oral films must be less than 30 seconds, as this is
 475 the era of development for oral film technology these are considered to be standard

476 guidelines. Pharmacopoeia disintegrating test apparatus was used for this study.
 477 Typical disintegration time for strips was 5–30s. In this research the disintegration
 478 time observed for formulations F₁ to F₁₂ was 31, 30, 18, 19, 22, 19, 20, 20, 21, 20, 20, 32
 479 respectively.




480

481 **Figure 13:** Graph showing disintegration time of different formulations from F₁ - F₁₂.
 482 X-axis represents the formulations and y-axis represents the disintegration time in
 483 seconds.

484 4.13 *In vitro* Dissolution Studies

485 Dissolution studies were performed in *in vitro* experimental system i.e USP Apparatus
 486 I (Setouhi *et al.*, 2010). The dissolution observed for formulations F₁ to F₁₂ was 95.2%,
 487 92.4%, 93.0%, 104.7%, 94.30%, 95.9%, 106.6%, 101.4%, 95.6%, 96.2%, 96.7%,
 488 97.4% respectively.




489

490 **Figure 14:** Graph showing Dissolution of different formulations from F₁ - F₁₂ in
 491 percentage values. X-axis represents the formulations and y-axis represents the
 492 dissolution results in percentage. Dissolution studies were performed using high-
 493 pressure liquid chromatograph that was equipped with a UV detector at 231 nm and
 494 connected with computing system. Chromatographic column 25cm x 4.6mm (i.d.), 5μ
 495 Hypersil BDSC18. Glass fiber Filter (type GF/A available from Whatman. 20μL
 496 injection was inserted at a flow rate of 1.5ml/min at ambient temperature.

497

498 4.14 HPLC Analysis

499



500

501

502 **Figure 15:** HPLC Chromatogram of Sample 05A (Assay). X-axis represents the time
503 in minutes and y-axis represents the height of peak in mAU. The graph shows peak
504 area of 6106.45020 mAU at retention time of 1.809 minutes. The height of peak is
505 674.00757 mAU. High-pressure liquid chromatograph was equipped with a UV
506 detector at 231 nm and connected with computing system. Chromatographic column
507 25cm x 4.6mm (i.d.), 5 μ Hypersil BDSC18.Glass fiber Filter (type GF/A available
508 from Whatman.20 μ L injection was inserted at a flow rate of 1.5ml/min at ambient
509 temperature.

510

511

512

513

514

515

516

517

518 **5 DISCUSSION**

519 All the fast dissolving oral films (Formulation F₁-F₁₂) containing alprazolam were
520 prepared by using Hydroxypropyl methyl cellulose E5, Hydroxypropyl methyl
521 cellulose (E15) (alone or in combination), PEG-400, aspartame and citric acid
522 monohydrate using solvent casting method. Water was used to prepare solution.
523 Solvent casting method has some advantages over other film forming methods i.e
524 distribution of casted film in a better and uniform way with stable dimensions
525 (Siemann, 2005). Films obtained are more clearly showing highest purity and lowest
526 degree of haze. No technical expertise is required (Mahajan, 2012).

527 Fourier Transform Infrared spectrophotometer (FT-IR) spectral measurements were
528 performed. The pure drug and physical mixture were mixed together for analysis of
529 interaction between these mixtures. The structure of alprazolam showed the aromatic
530 functional groups (C-C) of arene, azarene, benzene and heteroarene. CHN containing
531 amine group, (N-N) imine group, iminyl group, halogen containing arylchloride and
532 arylhalide and a leaving group. The peak area near 1400 to 1600cm⁻¹ represents
533 aromatic functional groups. Peak area near 1330-1400cm⁻¹ represents C-H bonding in
534 structure of alprazolam, peak area near 1420cm⁻¹ represents CHN bonding in
535 structure. IR band of (N-N) imine group appeared around 3150-3300cm⁻¹. From these
536 results it was concluded that all the major functional groups of alprazolam showed
537 their characteristic peaks and there was no any significant interaction between
538 alprazolam and excipients used.

539 Linearity or standard calibration curve is the straight line curve that must show the
540 linear response of API at increased concentrations. Standard calibration curve was
541 developed for alprazolam by developing different concentrations of drug substance
542 (Kunte, Tandale, 2010).

543 Linearity experiments were conducted to identify the range over which Alprazolam
544 exhibit linear response. The stock solution of Alprazolam was prepared by dissolving
545 50 mg of finely powder homogeneous sample of Alprazolam into 100 mL of mobile
546 phase and different concentrations of Alprazolam were prepared. The stock solution
547 was gravimetrically diluted in mobile phase to concentrations of 0.005mg/ml,
548 0.01mg/ml, 0.02mg/ml, 0.03mg/ml, 0.04mg/ml and 0.05 mg/ml respectively and
549 readings were taken to observe peak areas for relationship between concentration in

550 percentage and peak area in mAU. It was observed that as the concentration of anylate
551 increses the peak area also increases. A Linear straight line shows that the analytical
552 method is validated.

553 Micrometer screw guage was used to moniter the uniformity in thickness of films
554 (Khatoon *et al.*, 2014). Six samples from each formulation were examined and
555 thickness was checked from four corners and middle point of film and average was
556 taken. Thickness should be 5-200 μ m (Collins *et al.*, 1987). The thickness of film was
557 measured by micrometer screw gauge at different strategic locations i.e from four
558 corners and center of film. Similarly the variation of mass between different films
559 will also be measured by measuring 1cm² size of three films from each formulation.
560 Thickness and mass of films are closely co related with each other (MADDELA *et al.*,
561 2019).

562 (Sandeep *et al.*, 2011) research showed the thickness of films measured by using
563 micrometer. Three readings from each formulation samples were noted and their
564 average was considered as final. Thickness of fast dissolving oral films of all
565 formulations must show uniform thickness. Films of formulations with more
566 concentration of film forming polymer must show more thickness and vice versa. It is
567 also clear that the thickness of fast dissolving oral films is directly proportional to the
568 concentration of polymer (Bais *et al.*, 2016), (Rathore *et al.*, 2019)

569 Different formulations were evaluated against different concentrations of film
570 formers and it was observed that as the concentration of PVA (Film Former) was
571 increased thickness of fast dissolving film is increased and such type of findings
572 were also observed previously (Rajni *et al.*, 2014). Our results showed thickness
573 of film in between 35 to 70 μ m, furthermore it was observed that the thickness of
574 fast dissolving oral film was low i.e 35 μ m for formulation F1 which had lowest
575 concentration i.e350mg of film forming polymer HPMC E5 and highest i. e 70 μ m
576 for the formulation F12 which had highest quantity of carrier concentration i.e
577 300mg HPMC E 15 and 200mg HPMC E 5. Hence it is concluded from the results
578 observed that film forming polymers also endure the thickness of film as the films
579 containing more concentration of polymer have more thickness and vice versa. It
580 was noticed that films formed by HPMC E5 provided lower thickness compared to
581 films of HPMC E15.

582 Films must be characterized for tackiness and dryness as the tackiness of film is the
583 ability with which film stuck to the surface of paper or foil (Khatoon *et al.*, 2014).

584 Tackiness of film could be controlled by controlling environmental parameters i.e
585 temperature, relative humidity etc. It is reported in literature that higher relative
586 humidity gives high tackiness and vice versa (Bais *et al.*, 2016).

587 In this research films were physically observed for tackiness and dryness and it was
588 observed that all the films were dust free and dry and no print was observed. It was
589 further cleared from transparency test of films. Where the transparency of all the
590 samples was within 82.2% to 100.6%. However it was observed that tackiness of
591 formulation F₁₁ was found maximum and for formulation F₁₂, it was minimum.

592 The stressing force applied outward to the film at its edges until it breaks is the tensile
593 strength of film. To calculate the value of tensile strength the force required to rupture
594 or break the film was divided with cross sectional dimensions of film i.e thickness and
595 the width of film (Dahima *et al.*, 2010). It was calculated by the applied load at
596 rupture divided by the cross-sectional area of the strip as given in the equation below:

$$597 \quad \text{Tensile strength} = \text{Load at failure} \times 100 / \text{Strip thickness} \times \text{Strip width}$$

598 Tensile strength of film was found to be increased by increasing contents of
599 Plasticizer PEG-400 which may increase the elasticity of the final formulation. Also
600 contents of film former like PVA may increase the elasticity and hence the tensile
601 strength of film due to elastic nature of film forming polymer (Rajni *et al.*, 2014).

602 Tensile strength of film is essential to ascertain the elasticity of the film as this is
603 directly related to the folding endurance and percent elongation in the strip (Khatoon
604 *et al.*, 2014).

605 In current research, the tensile strength of fast dissolving film was lowest for
606 formulation F₁ which contained lowest concentration of film forming agent with no
607 plasticizer and it was highest for formulation F₇ which had highest concentration of
608 plasticizer.

609 Hence it can be concluded from the results observed that the films containing no
610 plasticizer and lowest amount of film former had less tensile strength compared to
611 films in which film forming polymer and plasticizer was used.

612 The percent increase in length of film when a stretching force is applied to it is called
613 the percent elongation. It is the change in shape or deformation of film divided by its
614 cross sectional area (Dahima *et al.*, 2010). Percent elongation was performed for six
615 samples from each formulation by using tensile strength tester. Generally elongation
616 of film increases as the plasticizer content increases. It could also be calculated by
617 subtracting the final length of film from its initial length i.e before applying stretching
618 force and dividing with initial length of strip. Generally elongation of strip increases
619 as the plasticizer content increases.

620 Percent Elongation of film was found to be increased by increasing contents of
621 Plasticizer PEG-400 which may increase the elasticity of the final formulation. Also
622 contents of film former like PVA may increase the elasticity and hence the Percent
623 Elongation of film due to elastic nature of film forming polymer (Rajni *et al.*,
624 2014).Percent elongation of film is also essential to ascertain the elasticity of the film
625 as this is directly related to the folding endurance and tensile strength in the strip that
626 effects the wettability and dissolution of film through salivary contents (Cilurzo *et al.*,
627 2008).

628 Here in this piece of work the percent elongation of fast dissolving film was also
629 observed lowest for formulation F1 which had lowest concentration of film forming
630 agent with no plasticizer and it was highest for formulation F7 which had highest
631 concentration of plasticizer.

632 It is concluded from the results observed that the films containing no plasticizer and
633 lowest amount of film former had less percent elongation as compared to films in
634 which film forming polymer and plasticizer had been used.

635 Folding endurance is the ability of film that how many times it could be folded
636 without any crack or breakage (Dahima *et al.*, 2010).

637 Folding endurance of film was increased with increase in concentration of plasticizer
638 PEG-400 which may increase the elasticity of the final formulation. Also contents of
639 film former like PVA may increase the elasticity and hence the Folding Endurance of
640 film due to elastic nature of film forming polymer (Rajni *et al.*, 2014).

641 Here in this research the folding endurance of fast dissolving film was also observed
642 lowest for formulation F₁ which had lowest concentration of film forming agent with

643 no plasticizer and it was highest for formulation F₇ which had highest concentration
644 of plasticizer.

645 Hence it is concluded from the results observed that the films containing no
646 plasticizer and lowest amount of film former had less folding endurance as compared
647 to films in which film forming polymer and plasticizer had been used.

648 Transparency is the test performed to evaluate the percent transmittance of transparent
649 films using U.V Spectrophotometer. Transmittance of films was determined at λ_{\max} of
650 600 nm. Transparency shows that how much the film is free from any foreign particle
651 or any haziness of casted solution as the transparency of film matters for its physical
652 appearance. Six film samples were examined by putting their suitable size as per cell
653 of U.V spectrophotometer. The transmittance of films was determined at 600 nm. The
654 transparency of the films was calculated as follows:

$$655 \text{ Transparency} = (\log T_{600})/b = -\epsilon c$$

656 In this equation T represents the transmittance of film, b is the thickness of film and c
657 is the concentration at which formulation was developed.

658 Results discussed by (Rajni *et al.*, 2014) in which transparency of film were tested
659 using rectangular piece of films by putting it in inner side of U.V cell and
660 transmittance was observed at 600nm. All the formulations showed transmittance of
661 above 90%. Transparency was observed for different samples of formulations using
662 U.V Spectrophotometer and results were observed (Sandeep *et al.*, 2011).

663 Here in this research transparency was observed by U.V Spectrophotometer at
664 wavelength of 600nm and setting U.V parameters at transmittance. It was observed
665 that transparency of formulation F11 was maximum and for formulation F12, it was
666 minimum.

667 From the above observation it was concluded that transmittance of film was effected
668 by its extent of transparency that in turn affected by solubility and compatibility of
669 API and excipients.

670 Contact angle determines the extent to which film could be adhered to water and show
671 its wettability that in turn determines the disintegration and dissolution properties of
672 the film. It was determined by putting a drop of distilled water on film and image was
673 recorded within 10 seconds after placement of drop. Angle of film was measured from

674 both sides of drop and then average was calculated for each formulation. The contact
675 angle must be within 0-180° (Pallavi *et al.*, 2014), (Soorya Sankar, 2017).

676 In this research also contact angle was observed by placing a drop of distilled water
677 over film and angle at which water drop had been spread over film was measured by
678 measuring droplet height, width, volume and area. It was observed that contact angle
679 was maximum for film under formulation F7 and was minimum for formulation F1.

680 Drug contents should be within the range designed by any standard official
681 Pharmacopoeia. Drug contents for all the formulations were 106% for X1, 95.0% for
682 X2, 97.0% for X3 and 99.0% for formulation X4 results discussed by (Nitesh
683 Chauhan *et al.*, 2012).

684 In this research work drug content by using HPLC were observed similar and within
685 pharmacopoeia limits and was observed minimum for formulation F1 and was
686 maximum for formulations F8 and F11.

687 Disintegration time is the time taken by the film to disintegrate in water. According to
688 CDER guidelines the time taken by oral films must be less than 30 seconds, as this is
689 the era of development for oral film technology these are considered to be standard
690 guidelines. Pharmacopoeia disintegrating test apparatus was used for this study.
691 According to most research data available the average disintegration time for oral film
692 is from five to thirty seconds.

693 Disintegration time study was carried out and time of disintegration was measured in
694 seconds. All the formulations were disintegrated within 40seconds and similar results
695 were seen in a previous investigation (Sandeep *et al.*, 2011). Different formulations
696 were evaluated against different concentrations of film formers and it was noticed that
697 as the concentration of PVA (Film Former) was increased, disintegration time of fast
698 dissolving film was also increased. Our results were in line with results reported
699 earlier (Rajni *et al.*, 2014). A study aimed to design and evaluate new disintegration
700 protocols as an attempt to select the best approach that would reflect the *in-*
701 *vivo* disintegration time in comparison to formerly reported procedures. Novel
702 methods were designed, namely; the frame, the cell, and the agar plate methods, and
703 compared to the previously reported methods; clamp and modified USP disintegration
704 methods. Different ODFs were formulated using various viscosity grades of
705 hydroxypropylmethyl cellulose. The mechanical characteristics of the prepared films

706 were studied using texture analyzer and film folding endurance test. The resultant
707 disintegration time of the films measured by the aforementioned methods were
708 compared and correlated with its *in-vivo* time. Interestingly, the results obtained
709 through the use of the cell method for the low viscosity polymers did not vary
710 significantly from that of their *in-vivo* results ($p>0.05$). Moreover, the disintegration
711 time of all polymeric films determined by the cell method revealed independently on
712 their viscosity the highest correlation with *in-vivo* disintegration time ($R^2 = 0.999$).
713 Such findings indicated the suitability of the cell method in predicting *in-vivo*
714 disintegration time of low viscosity polymeric films. (Saab *et al.*, 2019)

715 Disintegration time was observed within 18 to 32 seconds and formulation F₁₂ was
716 disintegrated in greater time i.e 32 seconds compared to F₃, which disintegrated too
717 quickly i.e in 18seconds.

718 The disintegration time of the fast dissolving films depends upon the type and
719 percentage of film forming polymers used in the film formulations. The increase in
720 amount of polymer increased the disintegration which is correlated with hindrance
721 offered by polymer (Garsuch *et al.*, 2010).

722 *In-vitro* dissolution study was carried out in USP Apparatus I and cumulative drug
723 percentage was calculated using U.V Spectrophotometer. Formulations exhibited
724 maximum dissolution at 5minutes (Sandeep *et al.*, 2011). Studies showed that fast
725 dissolving oral films of vitamin B12 for pregnant women present better dissolution
726 and disintegration results than in the form of tablets (BEYATRICKS, 2019).

727 In present research dissolution test was performed using Apparatus-1. The dissolution
728 medium used was consisted of in potassium phosphate buffer media. Dissolution test
729 for all the formulations was performed and relevant chromatograms for blank,
730 standards and samples were evaluated. Dissolution was observed minimum for
731 formulation F₂ i.e 92.40% at 1.811minute and was maximum for formulations F₇ i.e
732 106.6% at 1.813 minutes. Among the formulations F₁, F₂, F₃, F₅, F₆, F₉ showed the
733 lowest drug release i.e near or below 95%. However for formulations F₄, F₇, F₈, F₁₀, F₁₁
734 showed highest drug release i. e near or above 100%. This is due to more
735 concentration of HPMC E5 in these formulations and more wettability of HPMC E5
736 in dissolution medium. While comparing formulation F₂ containing 1.96% of HPMC

737 with that of F₇ containing 2.16% of HPMC F₂ shows lower drug release due to less
738 concentration of HPMC at retention times of 1.811 and 1.813 minutes respectively.

739 **6 CONCLUSION**

740 Fast dissolving oral films of alprazolam were successfully prepared using solvent
741 casting method. Two polymers (HPMC E5, HPMC E15) were analyzed for the
742 purpose as alone or combination with varied concentrations of plasticizers (PEG-
743 6000, PEG-400). Smooth texture and adequate mechanical strengths were achieved
744 for all formulations. The optimized formulation (F₇) offered almost 106.60% of total
745 drug release after 1.813 minutes, good tensile strength (5.38 N/cm²) and distinct
746 morphology. The overall results of the study concluded that alprazolam fast
747 dissolving oral films have potential to act as fast dissolving drug delivery system for
748 fast action of the drug.

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766 **7 References**

- 767 Akca, G., Özdemir, A., Öner, Z. G., & Şenel, S. (2018). Comparison of different
768 types and sources of chitosan for the treatment of infections in the oral cavity.
769 *Research on Chemical Intermediates*, 44(8), 4811-4825.
- 770 Arya, A., Chandra, A., Sharma, V., & Pathak, K. (2010). Fast dissolving oral films: an
771 innovative drug delivery system and dosage form. *International Journal of*
772 *Chem Tech Research*, 2(1), 576-583.
- 773 Bala, R., Pawar, P., Khanna, S., & Arora, S. (2013). Orally dissolving strips: A new
774 approach to oral drug delivery system. *International journal of*
775 *pharmaceutical investigation*, 3(2), 67.
- 776 BEYATRICKS, J. (2019). Development of Fast Dissolving Oral Films Containing
777 Vitamin B6 for Nausea and Vomiting of Pregnancy (NVP). *Journal of Drug*
778 *Delivery and Therapeutics*, 9(3), 51-59.
- 779 Bhyan, B., Jangra, S., Kaur, M., & Singh, H. (2011). Orally fast dissolving films:
780 innovations in formulation and technology. *Int J Pharm Sci Rev Res*, 9(2), 9-
781 15.
- 782 Cilurzo, F., Cupone, I. E., Minghetti, P., Selmin, F., & Montanari, L. (2008). Fast
783 dissolving films made of maltodextrins. *European Journal of Pharmaceutics*
784 *and Biopharmaceutics*, 70(3), 895-900.
- 785 Collins, L., & Dawes, C. (1987). The surface area of the adult human mouth and
786 thickness of the salivary film covering the teeth and oral mucosa. *Journal of*
787 *dental research*, 66(8), 1300-1302.
- 788 Damle, B., Tarabar, S., Kuruganti, U., Crownover, P., & LaBadie, R. (2013).
789 Bioequivalence of alprazolam sublingual tablet formulation and alprazolam
790 immediate release tablet in healthy volunteers. *J Bioequiv Availab*, 5(4), 149-
791 153.
- 792 Dixit, R., & Puthli, S. (2009). Oral strip technology: overview and future potential.
793 *Journal of controlled release*, 139(2), 94-107.
- 794 Evans, R. L. (1993). Alprazolam-XR: A pharmacokinetic review. *Psychiatric Annals*,
795 23(10), 8-9.
- 796 Gandhi, R. B., & Robinson, J. R. (1994). Oral cavity as a site for bioadhesive drug
797 delivery. *Advanced drug delivery reviews*, 13(1-2), 43-74.

798 Garsuch, V., & Breitreutz, J. (2010). Comparative investigations on different
799 polymers for the preparation of fast-dissolving oral films. *Journal of*
800 *Pharmacy and Pharmacology*, 62(4), 539-545.

801 Gwee, K., Leong, Y., Graham, C., McKendrick, M., Collins, S., Walters, S., . . . Read,
802 N. (1999). The role of psychological and biological factors in postinfective gut
803 dysfunction. *Gut*, 44(3), 400-406.

804 MADDELA, S., & NALLURI, B. N. (2019). DEVELOPMENT OF
805 ZOLMITRIPTAN MOUTH DISSOLVING FILMS: FORMULATION
806 VARIABLES, MECHANICAL PROPERTIES, AND IN VITRO DRUG
807 RELEASE STUDIES. *DEVELOPMENT*, 12(4).

808 Mahaguna, V., Talbert, R. L., Peters, J. I., Adams, S., Reynolds, T. D., Lam, F. Y., &
809 Williams III, R. O. (2003). Influence of hydroxypropyl methylcellulose
810 polymer on in vitro and in vivo performance of controlled release tablets
811 containing alprazolam. *European Journal of Pharmaceutics and*
812 *Biopharmaceutics*, 56(3), 461-468.

813 Mandeep, K., Rana, A., & Nimrata, S. (2013). Fast Dissolving Films: An Innovative
814 Drug Delivery System. *International Journal of Pharmaceutical Research &*
815 *Allied Sciences*, 2(1).

816 Márquez, M., Arenoso, H., & Caruso, N. (2011). Efficacy of alprazolam sublingual
817 tablets in the treatment of the acute phase of panic disorders. *Actas Esp*
818 *Psiquiatr*, 39(2), 88-94.

819 NIMBAL, G. M., Halse, S., & NAZIYA, F. G. (2013). Modelling and simulation of
820 thermal actuator using polysilicon material. *Journal of Pure Applied and*
821 *Industrial Physics Vol*, 3(3), 193-228.

822 O'Sullivan, G., Noshirvani, H., Basoglu, M., Marks, I., Swinson, R., Kuch, K., &
823 Kirby, M. (1994). Safety and Side-effects of Alprazolam Controlled Study in
824 Agoraphobia with Panic Disorder. *The British Journal of Psychiatry*, 165(1),
825 79-86.

826 Pandya, K. (2013). Fast dissolving films: a novel approach to oral drug dilivery. *Int.*
827 *Jour. of Pharmamedix India*, 1(2).

828 Patel, A. R., Prajapati, D. S., & Raval, J. A. (2010). Fast dissolving films (FDFs) as a
829 newer venture in fast dissolving dosage forms. *International journal of drug*
830 *development and research*, 2(2), 232-246.

831 Rabinowitz, J. D., & Zaffaroni, A. C. (2004). Delivery of alprazolam, estazolam,
832 midazolam or triazolam through an inhalation route: Google Patents.

833 Rathore, R., Gupta, A. K., & Parashar, A. K. (2019). Formulation and Evaluation of
834 fast dissolving films of Granisetron Hydrochloride. *Journal of Drug Delivery
835 and Therapeutics*, 9(2-A), 36-38.

836 Rowland, M. (1972). Influence of route of administration on drug availability.
837 *Journal of pharmaceutical sciences*, 61(1), 70-74.

838 Saab, M., & Mehanna, M. M. (2019). Disintegration time of orally dissolving films:
839 various methodologies and in-vitro/in-vivo correlation. *Die Pharmazie-An
840 International Journal of Pharmaceutical Sciences*, 74(4), 227-230.

841 Saini, S., Nanda, A., & Dhari, J. (2011). Formulation, development & evaluation of
842 oral fast dissolving anti-allergic film of levocetirizine dihydrochloride. *Journal
843 of Pharmaceutical Sciences and Research*, 3(7), 1322.

844 Shirsand, S., Suresh, S., Swamy, P., Kumar, D. N., & Rampure, M. (2008). Design
845 and evaluation of fast dissolving tablets of clonazepam. *Indian journal of
846 pharmaceutical sciences*, 70(6), 791.

847 Siemann, U. (2005). Solvent cast technology—a versatile tool for thin film production
848 *Scattering methods and the properties of polymer materials* (pp. 1-14):
849 Springer.

850 Yalkowsky, S. H., Valvani, S. C., & Johnson, B. W. (1983). In vitro method for
851 detecting precipitation of parenteral formulations after injection. *Journal of
852 pharmaceutical sciences*, 72(9), 1014-1017.

853

854